Medpace (NASDAQ:MEDP) Sets New 1-Year High – What’s Next?

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) reached a new 52-week high on Tuesday . The company traded as high as $626.26 and last traded at $612.9310, with a volume of 87508 shares trading hands. The stock had previously closed at $618.49.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on MEDP. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Mizuho increased their price objective on shares of Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th. Rothschild Redb lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Barclays increased their price target on Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a report on Friday, October 24th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $487.18.

Medpace Price Performance

The stock’s 50-day moving average price is $551.90 and its 200 day moving average price is $436.91. The firm has a market capitalization of $17.36 billion, a PE ratio of 43.12, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.Medpace’s revenue was up 23.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 36,196 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the transaction, the chief executive officer directly owned 925,799 shares in the company, valued at $440,587,744.10. This represents a 3.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Jesse J. Geiger sold 21,503 shares of the business’s stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the completion of the sale, the president owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This represents a 58.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 223,166 shares of company stock worth $127,478,349. Corporate insiders own 20.30% of the company’s stock.

Hedge Funds Weigh In On Medpace

Large investors have recently bought and sold shares of the business. Fifth Third Wealth Advisors LLC lifted its holdings in shares of Medpace by 2.6% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after buying an additional 19 shares during the period. BOKF NA grew its holdings in Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after acquiring an additional 20 shares during the period. HighPoint Advisor Group LLC raised its position in Medpace by 2.8% during the third quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock valued at $416,000 after acquiring an additional 22 shares in the last quarter. Portside Wealth Group LLC lifted its holdings in Medpace by 2.5% in the second quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock valued at $342,000 after acquiring an additional 27 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. boosted its position in Medpace by 35.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after purchasing an additional 27 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.